Lepercq Multi Asset Fund Invests $169,000 in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Lepercq Multi Asset Fund bought a new position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 22,700 shares of the company’s stock, valued at approximately $169,000. Lifecore Biomedical comprises approximately 0.1% of Lepercq Multi Asset Fund’s portfolio, making the stock its 5th biggest position. Lepercq Multi Asset Fund owned approximately 0.06% of Lifecore Biomedical at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. ARS Investment Partners LLC bought a new stake in Lifecore Biomedical in the fourth quarter valued at about $74,000. Steward Partners Investment Advisory LLC grew its stake in Lifecore Biomedical by 61.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 27,184 shares of the company’s stock valued at $202,000 after acquiring an additional 10,320 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Lifecore Biomedical by 23.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 74,427 shares of the company’s stock valued at $553,000 after acquiring an additional 13,922 shares during the period. Creative Planning acquired a new position in Lifecore Biomedical in the third quarter valued at about $69,000. Finally, Jane Street Group LLC grew its stake in Lifecore Biomedical by 101.7% in the third quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock valued at $179,000 after acquiring an additional 18,277 shares during the period. Institutional investors own 83.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on LFCR shares. Craig Hallum boosted their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 22nd. Stephens reissued an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

Lifecore Biomedical Stock Performance

Shares of NASDAQ LFCR opened at $6.18 on Friday. The stock has a 50 day moving average price of $6.17 and a 200 day moving average price of $6.02. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $8.01. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. The stock has a market capitalization of $228.81 million, a PE ratio of -11.04 and a beta of 0.96.

Lifecore Biomedical (NASDAQ:LFCR) last issued its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Analysts predict that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Lifecore Biomedical

In other Lifecore Biomedical news, CEO Paul Josephs acquired 17,000 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were purchased at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at approximately $3,212,775.58. This represents a 3.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 32.20% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.